Labcorp (NYSE:LH – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 18.100-18.550 for the period, compared to the consensus estimate of 17.990. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on LH shares. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Bank of America boosted their price target on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Weiss Ratings raised Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Robert W. Baird increased their price objective on Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $318.67.
View Our Latest Research Report on LH
Labcorp Price Performance
Labcorp (NYSE:LH – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. During the same period in the previous year, the company posted $4.35 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, analysts forecast that Labcorp will post 18 EPS for the current fiscal year.
Labcorp Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.
Insider Transactions at Labcorp
In other news, EVP Bryan T. Vaughn sold 234 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the transaction, the executive vice president owned 6,746 shares of the company’s stock, valued at approximately $1,930,637.74. The trade was a 3.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the completion of the sale, the chief executive officer owned 107,234 shares in the company, valued at approximately $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 6,991 shares of company stock valued at $1,796,696. Company insiders own 0.84% of the company’s stock.
Labcorp News Summary
Here are the key news stories impacting Labcorp this week:
- Positive Sentiment: Labcorp reported second-quarter adjusted EPS of $4.99, ahead of the approximately $4.78–$4.79 consensus, while revenue rose 5.8% year over year to $3.73 billion, also exceeding expectations. Adjusted margins expanded, and earnings increased from $4.35 per share in the year-earlier period. Reuters article
- Positive Sentiment: Management raised its fiscal 2026 outlook, forecasting EPS of $18.10 to $18.55 and revenue of approximately $14.71 billion to $14.83 billion. The increase reflects steady diagnostic-testing demand and continued growth in drug-development services. Labcorp second-quarter results release
- Positive Sentiment: Both major segments contributed to growth: Diagnostics Laboratories revenue increased 5.5% to $2.90 billion, while Biopharma Laboratory Services revenue rose 6.5% to $836.2 million. Labcorp also authorized an additional $1 billion for share repurchases, supporting potential per-share earnings growth. Labcorp revenue and capital allocation report
- Neutral Sentiment: Although the earnings and revenue beats were favorable, shares initially faced pressure in premarket trading, suggesting that investors may have expected an even stronger outlook or operating performance. The subsequent recovery indicates the market ultimately gave greater weight to the guidance increase and buyback authorization. Zacks earnings analysis
- Negative Sentiment: Reported insider activity was one-sided, with executives recording 14 sales and no purchases over the past six months. While these transactions may reflect diversification rather than a view on fundamentals, they could weigh modestly on sentiment. Insider trading data
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of LH. Wellington Management Group LLP boosted its stake in shares of Labcorp by 15.9% during the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock valued at $604,488,000 after purchasing an additional 289,029 shares in the last quarter. Invesco Ltd. raised its holdings in Labcorp by 7.1% in the 4th quarter. Invesco Ltd. now owns 1,391,978 shares of the medical research company’s stock valued at $349,220,000 after buying an additional 91,867 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Labcorp by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,304,191 shares of the medical research company’s stock worth $327,215,000 after buying an additional 57,635 shares during the period. JPMorgan Chase & Co. boosted its position in Labcorp by 19.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,287,177 shares of the medical research company’s stock worth $322,927,000 after buying an additional 213,136 shares during the period. Finally, Bank of America Corp DE grew its holdings in Labcorp by 4.0% during the 3rd quarter. Bank of America Corp DE now owns 726,090 shares of the medical research company’s stock worth $208,431,000 after acquiring an additional 27,879 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.
Labcorp Company Profile
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.
Read More
- Five stocks we like better than Labcorp
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
